GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates A/S (OCSE:VIRO) » Definitions » Price-to-Free-Cash-Flow

ViroGates A/S (OCSE:VIRO) Price-to-Free-Cash-Flow : N/A (As of May. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is ViroGates A/S Price-to-Free-Cash-Flow?

As of today (2024-05-24), ViroGates A/S's share price is kr6.90. ViroGates A/S's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr-2.35. Hence, ViroGates A/S's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for ViroGates A/S's Price-to-Free-Cash-Flow or its related term are showing as below:

OCSE:VIRO's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 34.18
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

ViroGates A/S's Free Cash Flow per Share for the three months ended in Mar. 2024 was kr-0.59. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was kr-2.35.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 2.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 2.60% per year.

During the past 8 years, ViroGates A/S's highest 3-Year average Free Cash Flow per Share Growth Rate was 2.20% per year. The lowest was -32.20% per year. And the median was -5.20% per year.


ViroGates A/S Price-to-Free-Cash-Flow Historical Data

The historical data trend for ViroGates A/S's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroGates A/S Price-to-Free-Cash-Flow Chart

ViroGates A/S Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

ViroGates A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ViroGates A/S's Price-to-Free-Cash-Flow

For the Medical Devices subindustry, ViroGates A/S's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroGates A/S's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates A/S's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ViroGates A/S's Price-to-Free-Cash-Flow falls into.



ViroGates A/S Price-to-Free-Cash-Flow Calculation

ViroGates A/S's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=6.90/-2.351
=N/A

ViroGates A/S's Share Price of today is kr6.90.
ViroGates A/S's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

ViroGates A/S  (OCSE:VIRO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


ViroGates A/S Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ViroGates A/S's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroGates A/S (OCSE:VIRO) Business Description

Traded in Other Exchanges
N/A
Address
Banevaenget 13, Birkerod, DNK, DK-3460
ViroGates A/S is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates A/S (OCSE:VIRO) Headlines

No Headlines